Non small cell lung cancer
Conditions
Interventions
Aggressive local stereotactic radiotherapy with third-line TKI vs. TKI only:No
Sponsors
Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 and <= 80 years; 2. Eligible participants had pathologically confirmed adenocarcinoma, gene sequencing confirmed EGFRm, stage IIIB-IV, receive either third-line tyrosine kinase inhibitor (TKI) treatment alone or with stereotactic radiotherapy; 3. According to RECIST 1.1, there is at least one measurable lesion; 4. Eastern Cooperative Oncology Group performance status score of <= 2; 5. No more than 5 metastases in total; 6. From 2018 to 2021, received medical treatment in Sichuan Provincial People's Hospital; 7. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Used imilar drugs in clinical trials; 3. Patients deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR (Objective Response Rate);PFS (Progress-Free Survival); | — |
Secondary
| Measure | Time frame |
|---|---|
| OS (Overall Survival); | — |
Countries
China
Contacts
Public ContactWang Xiaoshan
Sichuan Provincial People's Hospital
Outcome results
None listed